Literature DB >> 11450868

Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis.

P R Donald1, F A Sirgel, A Venter, D P Parkin, B W Van de Wal, A Barendse, E Smit, D Carman, J Talent, J Maritz.   

Abstract

The early bactericidal activity (EBA) of an antituberculosis agent is the rate of decrease in viable colony-forming units (CFU) per milliliter of sputum during the first 2 d of treatment of patients with previously untreated smear-positive pulmonary tuberculosis. The objective of this open randomized study was to evaluate the EBA of the combination of amoxicillin 3 g and clavulanic acid 750 mg. Ten patients with a mean age of 34 y and a mean weight of 56 kg received amoxicillin/clavulanic acid and 5 patients with a mean age of 34 y and a mean weight of 57 kg received no drug. In the patients receiving 1 dose of amoxicillin/clavulanic acid daily for 2 d the mean log10CFU/ml of sputum before treatment was 6.7402 (SD 0.539) and after 2 d of treatment 6.7046 (SD 0.609); the corresponding values in patients receiving no drug were 6.7823 (SD 0.563) and 6.7502 (SD 0.673), respectively. The EBA of 0.018 (SD 0.130) in patients receiving amoxicillin/clavulanic acid did not differ significantly from that of 0.016 (SD 0.069) in patients receiving no drug. It is unlikely that the combination of amoxicillin/clavulanic acid has an important place in the treatment of tuberculosis with the exception of those patients with multidrug-resistant tuberculosis who are otherwise therapeutically destitute.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11450868     DOI: 10.1080/00365540152029954

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  27 in total

Review 1.  New antituberculous drugs in development.

Authors:  Umesh G Lalloo; Anish Ambaram
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

2.  Recent advances in tuberculosis: New drugs and treatment regimens.

Authors:  Derek J Sloan; Geraint R Davies; Saye H Khoo
Journal:  Curr Respir Med Rev       Date:  2013-06-01

3.  Revisiting the β-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach.

Authors:  Shiqi Xiao; Haidan Guo; Warren S Weiner; Clinton Maddox; Chunhong Mao; Hendra Gunosewoyo; Shaaretha Pelly; E Lucile White; Lynn Rasmussen; Frank J Schoenen; Jeffrey Aubé; William R Bishai; Shichun Lun
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 4.  World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?

Authors:  Kelly E Dooley; Ekwaro A Obuku; Nadza Durakovic; Vera Belitsky; Carole Mitnick; Eric L Nuermberger
Journal:  J Infect Dis       Date:  2012-07-17       Impact factor: 5.226

5.  Oldie but goodie: Repurposing penicillin for tuberculosis.

Authors:  Amanda B Keener
Journal:  Nat Med       Date:  2014-09       Impact factor: 53.440

6.  Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Authors:  L Davies Forsman; C G Giske; J Bruchfeld; T Schön; P Juréen; K Ängeby
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

Review 7.  Current development and future prospects in chemotherapy of tuberculosis.

Authors:  Eric L Nuermberger; Melvin K Spigelman; Wing Wai Yew
Journal:  Respirology       Date:  2010-06-04       Impact factor: 6.424

8.  The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin.

Authors:  Radhika Gupta; Marie Lavollay; Jean-Luc Mainardi; Michel Arthur; William R Bishai; Gyanu Lamichhane
Journal:  Nat Med       Date:  2010-03-21       Impact factor: 53.440

Review 9.  Drug-Resistant Tuberculosis: Challenges and Progress.

Authors:  Sebastian G Kurz; Jennifer J Furin; Charles M Bark
Journal:  Infect Dis Clin North Am       Date:  2016-06       Impact factor: 5.982

10.  Comprehensive treatment of extensively drug-resistant tuberculosis.

Authors:  Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.